Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Gatifloxacin-based triple therapy as a third-line regimen for Helicobacter pylori eradication.

Journal of gastroenterology and hepatology - 1 Dec 2008

Nishizawa Toshihiro, Suzuki Hidekazu, Nakagawa Izumi, Iwasaki Eisuke, Masaoka Tatsuhiro, Hibi Toshifumi

Abstract excerpt

BACKGROUND AND AIM: This study was designed to investigate the efficacy of gatifloxacin (GAT)-based triple therapy as a third-line treatment for Helicobacter pylori (H. pylori) eradication, according to the assessment of the susceptibility to GAT and gyrA mutation. METHODS: Fourteen patients who had eradication failure following both clarithromycin-based triple therapy and metronidazole-based triple therapy, or...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to 2-Pyridinylmethylsulfinylbenzimidazoles
Share to Amoxicillin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clarithromycin

Share to DNA Gyrase

Share to Fluoroquinolones

Share to Metronidazole

Share to Proton Pump Inhibitors

Share to Rabeprazole

Source

Identifiers

PMID: 19120892
DOI: 10.1111/j.1440-1746.2008.05407.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Gatifloxacin-based triple therapy as a third-line regimen for Helicobacter pylori eradication.PMID 19120892Read ↗

Gatifloxacin resistance and mutations in gyra after unsuccessful Helicobacter pylori eradication in Japan.Semantic proximity Read ↗

Sitafloxacin resistance in Helicobacter pylori isolates and sitafloxacin-based triple therapy as a third-line regimen in Japan.Semantic proximity Read ↗

Efficacy of sitafloxacin-based rescue therapy for Helicobacter pylori after failures of first- and second-line therapies.Semantic proximity Read ↗

Sitafloxacin-based third-line rescue regimens for Helicobacter pylori infection in Japan.Semantic proximity Read ↗

Acquisition of double mutation in gyrA caused high resistance to sitafloxacin in Helicobacter pylori after unsuccessful eradication with sitafloxacin-containing regimensSemantic proximity Read ↗

Appropriate first-line regimens to combat Helicobacter pylori antibiotic resistance: an Asian perspective.Semantic proximity Read ↗

Update on quinolone-containing rescue therapies for Helicobacter pylori infection.Semantic proximity Read ↗

Efficacy of genotypic susceptibility-guided tailored therapy for Helicobacter pylori infection: A systematic review and single arm meta-analysis.Semantic proximity Read ↗

Gemifloxacin can partially overcome quinolone resistance of H. pylori with gyrA mutation in Taiwan.Semantic proximity Read ↗

Treatment of Helicobacter pylori infection: Where are we now?Semantic proximity Read ↗

Efficacies of Genotypic Resistance-Guided vs Empirical Therapy for Refractory Helicobacter pylori Infection.Semantic proximity Read ↗

Antibacterial Activity of Gatifloxacin (AM-1155, CG5501, BMS-206584), a Newly Developed Fluoroquinolone, against Sequentially Acquired Quinolone-Resistant Mutants and the norA Transformant of Staphylococcus aureusSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.